Tovaxin results

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Tovaxin results

Postby bromley » Wed Sep 28, 2005 7:00 am

User avatar
bromley
Family Elder
 
Posts: 1887
Joined: Fri Sep 10, 2004 3:00 pm

Advertisement

FDA Tovaxin phase IIb clinical trials protocol

Postby IHaveMS-com » Thu Nov 03, 2005 9:13 am

Here is a press release about the FDA phase IIb clinical trials and the protocol from the government clinical trials site.

<shortened url>

Press release on FDA approval
October 31, 2005 04:00 AM US Eastern Timezone

PharmaFrontiers Tovaxin(TM) Phase IIb Multiple Sclerosis Clinical Trial Protocol Accepted by FDA

THE WOODLANDS, Texas--(BUSINESS WIRE)--Oct. 31, 2005--PharmaFrontiers Corp. (OTCBB: PFTR), a company involved in the development and commercialization of cell therapies, announced today that the protocol for its Phase IIb clinical trial of Tovaxin(TM), a novel T cell therapeutic vaccine for Multiple Sclerosis (MS), has been accepted by the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER).


"PharmaFrontiers is very excited to receive a 'green light' from the FDA for our Phase IIb clinical trial. Our earlier open-label Phase I/II clinical trials not only gave us the safety and tolerability data we sought, but we also observed a trend towards a reduction in annualized relapse rate (ARR) in excess of 90%, the lowering of the myelin-peptide reactive T cells (MRTCs) in patients blood and the improvement in patients' clinical measures," said David B. McWilliams, chief executive officer of PharmaFrontiers. "The Tovaxin clinical program continues to show promising results and we believe that the completion of this Phase IIb clinical trial will allow us to launch a Phase III pivotal trial."

Tovaxin is a trivalent formulation of attenuated MRTCs, which are derived from peripheral blood and produced ex vivo as myelin basic protein (MBP), proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG) reactive T cells. MRTCs are believed to play a critical role in the pathogenesis of MS. Because several myelin antigens are described as potential autoantigens for MS, depletion of MRTCs using a trivalent formulation may have enhanced therapeutic effects.

This multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study is designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T Cell therapy with clinically isolated syndrome (CIS) and early relapsing-remitting MS (RR-MS) patients. Additionally, the study of these patients will evaluate biomarkers of Tovaxin's efficacy and to evaluate the effect of Tovaxin on immune deviation and epitope spreading.

"We believe that the protocol design will allow us to study the clinical effects of Tovaxin in a group of patients requiring a safe and effective therapy," said Edward J. Fox, M.D., Ph. D., director of The MS Clinic of Central Texas (Austin) and the lead principal investigator for the upcoming clinical studies. "During this two-arm, 52-week, parallel-group study, patients will be given five subcutaneous injections at 0, 4, 8, 12 and 24 weeks. The analyses will be performed at the end of the 52-week study to assess the safety and efficacy of Tovaxin. The primary efficacy variable is the cumulative number of gadolinium-enhancing lesions on T1-weighted MRI summed over the Week 28, 36, 44, and 52 MRIs. The secondary efficacy variables are the cumulative number of new gadolinium-enhancing lesions at Weeks 28-52, the change in T2-weighted lesion volume, and the annualized relapse rate. Of the 150 patients participating in the trial, 100 will receive Tovaxin and 50 will receive the placebo."

All patients who complete the trial will be eligible to participate in an optional one-year extension study, in which they will receive Tovaxin open-label. The open-label study is being planned under a different protocol that will be submitted to the FDA.

"A patient-specific therapeutic vaccination strategy, Tovaxin T cell vaccine is formulated using the MS patient's own myelin peptide-specific activated T cell lines, which are harvested and attenuated on the day of vaccine administration," said Jim C. Williams, Ph.D., PharmaFrontiers chief operating officer. "The shelf-life of the final product is approximately three days."

PharmaFrontiers will be conducting the Phase IIb with its clinical development partner, INC Research, Raleigh, NC.

-------------------------------------------------------------------

http://www.clinicaltrials.gov/ct/action ... CEDAA4DBDE

Autologous T Cell Vaccine for Multiple Sclerosis

This study is not yet open for patient recruitment.
Verified by PharmaFrontiers Corp October 2005

Sponsored by: PharmaFrontiers Corp
Information provided by: PharmaFrontiers Corp
ClinicalTrials.gov Identifier: NCT00245622


Purpose

A 1 year study to evaluate the efficacy, safety, and tolerability of Tovaxin T cell therapy in subjects with Clinically Isolated Syndrome (CIS) and Relapse-Remitting MS (RR-MS)
Condition Intervention Phase
Clinically Isolated Syndrome (CIS)
Relapse-Remitting Multiple Sclerosis (RR-MS)
Vaccine: Autologous T cell vaccine
Phase II


MedlinePlus related topics: Multiple Sclerosis


Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Tovaxin in Subjects With CIS or RR-MS

Further Study Details:
Primary Outcomes: To evaluate the efficacy, safety, and tolerability of Tovaxin TCV in subjects with CIS or RR-MS
Secondary Outcomes: To evaluate biomarkers of efficacy of Tovaxin TCV and effects of Tovaxin TCV on epitope spreading
Expected Total Enrollment: 150
Study start: December 2005
Last follow-up: July 2007

A 2 arm, 52 week parallel-group of Tovaxin versus placebo in subjects with CIS or RR-MS. Subjects who provide written, informed consent will complete screening and procurement assessments and provide blood to be used for vaccine production. Eligible subjects will be enrolled to receive either Tovaxin or placebo and will complete baseline assessments. Randomization and enrolled subjects will receive study treatment by subcutaneous injections at weeks 0, 4, 8, 12, and 24. Subjects will be monitored by CBC, serum chemistries, urinalysis, EDSS, MSFC, MSQLI, MRI, and monitor myelin reactive T cells for safety, efficacy, and tolerability of Tovaxin.
Eligibility

Ages Eligible for Study: 18 Years - 45 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:

Age 18 to 45 years old
Diagnosis of MS within the past 3 years according to the McDonald criteria (2001)
Baseline EDSS score between 0 and 3.5 inclusively
Exclusion Criteria:

Unable to produce T cell vaccine
Disease-modifying treatment for MS during the last 60 days
Diagnosis of progressive-relapsing, secondary progressive or primary progressive MS
Planned pregnancy
Any prior treatment with total lymphoid irradiation, cladribine, T cell or T cell receptor vaccination
Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier NCT00245622

Shannon M Inman 281-719-3405 MSBlood@pharmafrontierscorp.com



Study chairs or principal investigators

Edward J Fox, M.D., Ph.D., Principal Investigator, Central Texas Neurology Consultants
Jim C Williams, Ph.D., Study Director, PharmaFrontiers Corp
More Information

Study ID Numbers: TERMS Study; 2005-00
Last Updated: October 27, 2005
Record first received: October 20, 2005
ClinicalTrials.gov Identifier: NCT00245622
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-10-28
User avatar
IHaveMS-com
Family Elder
 
Posts: 213
Joined: Tue Jun 07, 2005 3:00 pm

Postby ewizabeth » Wed Dec 06, 2006 12:35 pm

Tim,

Are you still visiting here? I hope you'll be back to talk with us when the phase IIb trials are in full swing.
Take care, Ewizabeth Previously Avonex, Rebif & Copaxone RRMS ~Tysabri, 31 infusions, ended 9/09. Starting Copaxone 12/09, waiting for Cladribine to be approved in 2010.
User avatar
ewizabeth
Family Elder
 
Posts: 270
Joined: Fri Jun 25, 2004 3:00 pm
Location: Near Chicago

Postby Lyon » Wed Dec 06, 2006 1:08 pm

00
Last edited by Lyon on Mon Jun 20, 2011 3:25 pm, edited 1 time in total.
Lyon
Family Elder
 
Posts: 6063
Joined: Wed May 03, 2006 3:00 pm

Postby ewizabeth » Wed Dec 06, 2006 2:59 pm

Well thankfully, somebody mentioned Tim, that he'd been here before, and I didn't know he had been posting here, so I did a search. I'm hoping he'll come back with some little tidbits of info. :) I know that there are some that do not like the fact that his father was an investor, but hey, if one of my sons had MS, and I could help to bring a new treatment to fruition, and I had money, I'd do the same thing. I suppose he could have been a bit upfront about it though.

I have been known to be a bit impatient with investors with ulterior motives in the past though, I admit. Especially if they did not have relatives with MS, but just hung around touting a specific drug.
Take care, Ewizabeth Previously Avonex, Rebif & Copaxone RRMS ~Tysabri, 31 infusions, ended 9/09. Starting Copaxone 12/09, waiting for Cladribine to be approved in 2010.
User avatar
ewizabeth
Family Elder
 
Posts: 270
Joined: Fri Jun 25, 2004 3:00 pm
Location: Near Chicago


Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service

cron